

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During draft scope consultation consultees highlighted that:
--

- | |
|--|
| <ul style="list-style-type: none">• access to pulmonary hypertension services is needed to be able to screen and treat a larger group of patients to avoid any inequity• appropriate investigations need to be carried out locally, as patients may be unwilling to travel long distances for investigations, which may also entrench inequalities in access to treatment• people will need to be educated on how to prime and use the inhaler device needed for inhaled treprostinil• consideration will need to be given to how it would be administered in people who have issues with dexterity or carrying out complicated processes |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Issues related to implementation of a technology cannot be addressed by a technology appraisal, but the committee may choose to comment on these issues.
--

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name):Richard Diaz.....

Date: 7/3/2025